Cromolyn sodium in the treatment of asthma associated with aspirin hypersensitivity and nasal polyps.
The control of asthma by therapy with cromolyn sodium was studied in 28 adults with late-onset asthma associated with hypersensitivity to aspirin and nasal polyps. Four-week periods of treatment with the drug or a placebo were compared in a double-blind crossover study. A subsequent eight-week open trial in 20 patients was compared to their period of receiving placebo. There was slight but significant improvement in the forced expiratory volume in one second (FEV1; P less than 0.05) and the mean forced expiratory flow during the middle half of the forced vital capacity (FEF25-75%; P less than 0.05) after four weeks of therapy with cromolyn sodium and in the FEV1 (P less than 0.05), the forced vital capacity (P less than 0.01), and FEF25-75% (P less than 0.01) after an additional eight weeks of therapy with cromolyn sodium. The improvement in pulmonary function was not associated with changes in the peak expiratory flow rate, the symptoms of asthma, the doses of additional medication, or the index of disability. The dosage of corticosteroids in 22 patients receiving long-term therapy with steroids was no different between the four-week periods of treatment with placebo or drug but was significantly lower (P less than 0.05) during the eight-week open trial. We conclude that administration of cromolyn sodium has a therapeutic effect in this group of asthmatic patients.
D000328:Adult; D001241:Aspirin / Q000009:adverse effects; D001249:Asthma / Q000150:complications / Q000188:drug therapy*; D002648:Child; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D004342:Drug Hypersensitivity / Q000150:complications; D005540:Forced Expiratory Flow Rates; D005541:Forced Expiratory Volume; D006801:Humans; D009298:Nasal Polyps / Q000150:complications*; D009669:Nose Neoplasms / Q000150:complications; D010366:Peak Expiratory Flow Rate; D014797:Vital Capacity
D004205:Cromolyn Sodium; D001241:Aspirin